obtain a serum testosterone level to evaluate adequate gonadal suppression, restage the disease with radiographs and scans, maintain gonadal suppression, and plan the next therapeutic step.
if the patient experiences severe focal bone pain that requires regular use of narcotic analgesics, consider palliative radiation therapy.
restage with radiographs and scans, evaluate serum testosterone level if less than 50 ng/mL, and discontinue all hormonal therapy (LH-RH analogue and antiandrogen) for 4 to 8 weeks before planning the next therapeutic step.
if the patient has no symptoms, the workup shows that he has adequate gonadal suppression (serum testosterone <50 ng/mL), and the only evidence of disease progression is a rising prostate-specific antigen (PSA) and scans are unchanged, try a second-line hormonal therapy before chemotherapy is offered.
if the patient is on an antiandrogen in addition to a luteinizing hormone–releasing hormone (LH-RH) analogue, discontinue this for 4 weeks in the case of flutamide/nilutamide and for 8 weeks in the case of bicalutamide.
Assess the PSA doubling time (PSADT): if less than 6 months, consider treatment as soon as possible; otherwise, observation may be reasonable.
Evaluate the adequacy of gonadal suppression (check serum testosterone level) and plan for second-line endocrine manipulations.
Continue follow-up with regular PSA tests and restage when the patient becomes symptomatic.
Send the patient to an oncologist for initiation of chemotherapy.
Radiate the prostatic bed and the pelvis.
Administer a radiopharmaceutical.
Administer docetaxel, 75 mg/m2 every 3 weeks, and zoledronate, 4 mg monthly.
Wait until he becomes symptomatic.
Treat aggressively with high-dose bicalutamide, calcium, and vitamin
Plan for next endocrine treatment approach, including the infusion of zoledronate given 3 times yearly.
order radiation therapy followed by docetaxel.
give analgesics as needed and consider a workup when the PSA value rises.
order magnetic resonance imaging (MRI) of the spine to rule out cord compression.
add zoledronate to management.
consider radiation therapy.
perform a biopsy of the pelvic mass to rule out the neuroendocrine/anaplastic subtype.
treat with bicalutamide because the PSA level is still low.
send him for a colonoscopy because he probably has another cancer because the PSA value is negative.
administer radiation to the pelvis followed by docetaxel.
begin docetaxel because he has castration-resistant prostate cancer (CRPC).
chemotherapy with carboplatin and etoposide preceded or followed by irradiation.
radiation therapy followed by second-line hormonal therapy until progression; then offer chemotherapy.
a bronchoscopy, because of the histology (small cell carcinoma).
docetaxel combined with zoledronate.
radiation to the pelvis followed by ketoconazole and hydrocortisone.
Quality of life
All of the above
Thromboembolic events are usually prevented by prophylactic anticoagulation.
It is critical to use it combined with docetaxel.
It has no activity at all in CRPC.
It has significant single-agent activity in CRPC.
It adds significant toxicity to docetaxel without an apparent survival benefit.
it may cause fatigue and neurotoxicity.
it may cause modest elevation of liver function test results.
it may cause myelosuppression.
it may cause edema.
toxicity overrides quality of life benefits.
proliferation of osteoblasts.
increased osteoclastic activity.
depletion of osteoclasts.
They are mostly lytic, associated with a predominant osteoclastic effect associated with treatment.
There is increasing evidence that growth factors, cytokines, and other proteins may play a role in the development of bone metastases.
Hypercalcemia is common.
Pathologic fractures are common.
They are always osteoblastic, because of growth factor effects.
Side effects include anemia and renal dysfunction.
It rarely may cause osteonecrosis of the jaw in patients who are undergoing dental work.
It is approved for the treatment of hypercalcemia.
It reduces the increase in osteoclastic activity associated with androgen deprivation.
is usually seen in the first 3 months of treatment.
represents evidence of therapeutic benefit but not necessarily longer survival.
is seen in about 50% of patients receiving docetaxel treatment.
None of the above
Routine MRI of the brain should be considered in all CRPC patients.
It is seen in less than 1% of patients, except when they demonstrate the neuroendocrine phenotype.
Brain metastasis associated with small cell histology should be treated surgically.
It is common in patients progressing rapidly on hormonal therapy.
It is seen in about 25% of patients with CRPC.
They induce BCL2 phosphorylation.
They are antimitotic agents.
They cause radiosensitization in vitro.
They are associated with an increased accumulation of cells in the G2M phase of the cell cycle.
너는 정확하게 대답했다.
당신이 잘못 대답했습니다.
너는 시간이 없어.
점수 또는 평점을 저장하려면 로그인하거나 등록해야합니다.
텍스트에 적합한 오디오 언어를 설정하십시오.
단어를 강조 표시하여 학습을 향상시킵니다.
로그인 할 필요없이 퀴즈, 코스 및 플래시 카드를 재생할 수 있습니다. 그러나 점수를 저장하고 퀴즈, 코스 및 플래시 카드를 만들려면 로그인해야합니다. 오디오를 재생하려면 전문 계정에 로그인해야합니다.
학습을 한 차원 높여보십시오. 프로페셔널 계정으로 업그레이드하면 질문을 큰소리로 듣고 다른 많은 혜택을 누릴 수 있습니다.
귀하가 작성한 질문이나 답변에 대한 오디오가 생성됩니다.
많은 사람들이 그들이 배운 것을 듣고 더 잘 배웁니다. 외국어 학습을 위해 우리는 18 개 이상의 언어를 지원했습니다.
지원 언어로는 덴마크어, 네덜란드어, 영어, 프랑스어, 독일어, 아이슬란드 어, 이탈리아어, 일본어, 한국어, 노르웨이어, 폴란드어, 포르투갈어, 루마니아어, 러시아어, 스페인어, 스웨덴어, 터키어, 웨일스 어 등이 있습니다.
또한 단어를 소리내어 읽음으로써 자동 단어 단위 강조 기능을 지원합니다.
Apple App Store에서 볼 Topgrade 응용 프로그램을 선택하십시오.
Google Play에서 볼 수있는 Topgrade 앱을 선택합니다.